-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-12-26
FRES:NSD-Fresh2 Group Ltd (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.85Change
0.00 (0.00)%Market Cap
N/AVolume
N/AAnalyst Target
N/AN/A
Verdict
Values as of: 2024-12-26
COMMON STOCK | Biotechnology |
Last Closing
USD 0.85Change
0.00 (0.00)%Market Cap
N/AVolume
N/AAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
+2.47 (+0.61%) |
USD 120.60B |
REGN | Regeneron Pharmaceuticals Inc |
+2.21 (+0.31%) |
USD 84.94B |
ARGX | argenx NV ADR |
+2.05 (+0.33%) |
USD 36.54B |
ALNY | Alnylam Pharmaceuticals Inc |
-0.75 (-0.31%) |
USD 31.66B |
BGNE | BeiGene Ltd |
+3.06 (+1.68%) |
USD 20.24B |
UTHR | United Therapeutics Corporatio.. |
+3.23 (+0.90%) |
USD 16.18B |
MRNA | Moderna Inc |
+0.16 (+0.40%) |
USD 16.10B |
RPRX | Royalty Pharma Plc |
+0.17 (+0.67%) |
USD 15.27B |
SMMT | Summit Therapeutics PLC |
+0.28 (+1.47%) |
USD 13.67B |
INCY | Incyte Corporation |
-0.35 (-0.50%) |
USD 13.52B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
AGMI | Themes Silver Miners ETF | 5.04 % | 0.00 % |
+0.13 (+0.52%) |
USD 0.55M |
SILJ | Amplify ETF Trust | 3.74 % | 0.69 % |
-0.01 (0.52%) |
USD 0.64B |
SILG:LSE | Global X Silver Miners UC.. | 2.89 % | 0.00 % |
N/A |
N/A |
SILV:LSE | Global X Silver Miners UC.. | 2.89 % | 0.00 % |
N/A |
N/A |
SIL | Global X Silver Miners ET.. | 0.00 % | 0.65 % |
+0.26 (+0.52%) |
N/A |
SILV:SW | GLOBAL X SILVER MINERS UC.. | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -90.45% | 6% | D- | 3% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -90.45% | 6% | D- | 3% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -89.21% | 7% | C- | 4% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -89.21% | 7% | C- | 4% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -17.25% | 23% | F | 14% | F | ||
Dividend Return | -17.25% | 23% | F | 14% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 45.22% | 68% | D+ | 42% | F | ||
Risk Adjusted Return | -38.14% | 25% | F | 17% | F | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector